© 2018 MedPro Investors LLC

FEATURED CONTENT

February 27, 2018

SAN JOSE, Calif. – February 27, 2018 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced that it has created a joint venture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Hepalink), one of China’s leading pharmaceutical companies, to develop and gain regulatory approval for Aridis’ fully human monoclonal antibody (mAb) therapies for the greater China market.

READ MORE

January 24, 2018

B-TEMIA INC was announced as a finalist in the High Technology category for the FIDEIDES 2018 competition organized by the Chamber of Commerce of Quebec.

READ MORE

December 13, 2017

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins School of Medicine, as a new oncology advisor to Immunomic Therapeutics’ scientific advisory board.

READ MORE

December 05, 2017

B-TEMIA’s Dermoskeleton™ technology was featured in this news report by WCVB US.

WATCH VIDEO

November 22, 2017

ROCKVILLE, Md.–(BUSINESS WIRE)–Last week results from a study conducted by investigators in the laboratory of Duane Mitchell, M.D., Ph.D., director of the University of Florida Brain Tumor Immunotherapy Program and co-director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy, were presented at the 2017 Society for NeuroOncology (SNO) Annual Meeting.

READ MORE

September 12, 2017

Québec City, QC | September 12th, 2017 – B-TEMIA Inc., a Canadian biorobotic tech company and leader in the human augmentation market with its proprietary Dermoskeleton™ technology to aid mobility and Wistron Corporation, one of the world’s largest original design and manufacturers (ODMs) with revenues over CAD 25.5 billion, have signed an investment agreement whereby Wistron becomes a major shareholder in B-TEMIA. 

READ MORE

August 02, 2017

SAN JOSE, Calif. – August 2, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas aeruginosa.  The randomized, double-blinded, placebo-controlled trial is ongoing in 14 countries worldwide.

READ MORE

May 18, 2017

Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens of cytomegalovirus (CMV). Both companies are developing new approaches for generating vaccines for cancer.

READ MORE

April 11, 2017

Québec City, QC | April 11, 2017 – B-TEMIA Inc., a leader in the human augmentation market, announces today that it has licensed its bionic augmentation technology Dermoskeleton™ to Lockheed Martin, who is eyeing a new generation of industrial and military exoskeletons.

READ MORE

March 07, 2017

A Canadian company has rolled out a wearable device to help people with mobility issues counteract the ravages of aging and disease.

READ MORE

1 / 3

Please reload

SELECT MEDPRO NEWSLETTERS
Please reload